Wyeth Pharmaceutical’s (a Wyeth Division) investigational drug for major depressive disorder (MDD) -desvenlafaxine succinate (DVS-233), passed its Phase 3 clinical trial. The data and results of the study involving this novel serotonin-norepinephrine reuptake inhibitor (SNRI) have been presented at the 2006 American Psychiatric Association Annual Meeting in In summary, DVS-233 significantly improved the depressive symptoms in adult patients.
Wyeth discovered and developed desvenlafaxine succinate and submitted a New Drug Application (NDA) to the USFDA in December 2005 for the treatment of MDD.
Read more at Wyeth press release.
Comment Preview